{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Riester MR"],"funding":["NIA NIH HHS","National Institute of General Medical Sciences","National Institute on Aging","NIGMS NIH HHS"],"pagination":["1691-1700"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8522353"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["78(18)"],"pubmed_abstract":["Purpose
Pharmacists are well positioned to provide transitions of care (TOC) services to patients with heart failure (HF); however, hospitalizations for patients with HF likely exceed the capacity of a TOC pharmacist. We developed and validated a tool to help pharmacists efficiently identify high-risk patients with HF and maximize their potential impact by intervening on patients at the highest risk for 30-day all-cause readmission.Methods
We conducted a retrospective cohort study including adults with HF admitted to a health system between October 1, 2016, and October 31, 2019. We randomly divided the cohort into development (n = 2,114) and validation (n = 1,089) subcohorts. Nine models were applied to select the most important predictors of 30-day readmission. The final t"],"journal":["American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists"],"pubmed_title":["Development and validation of the Tool for Pharmacists to Predict 30-day hospital readmission in patients with Heart Failure (ToPP-HF)."],"pmcid":["PMC8522353"],"funding_grant_id":["R01AG065722","R21AG061632","RF1 AG061221","RF1AG061221","U54 GM115677","U54GM115677"],"pubmed_authors":["Collins C","Riester MR","Zullo AR","McAuliffe L"],"additional_accession":[]},"is_claimable":false,"name":"Development and validation of the Tool for Pharmacists to Predict 30-day hospital readmission in patients with Heart Failure (ToPP-HF).","description":"Purpose
Pharmacists are well positioned to provide transitions of care (TOC) services to patients with heart failure (HF); however, hospitalizations for patients with HF likely exceed the capacity of a TOC pharmacist. We developed and validated a tool to help pharmacists efficiently identify high-risk patients with HF and maximize their potential impact by intervening on patients at the highest risk for 30-day all-cause readmission.Methods
We conducted a retrospective cohort study including adults with HF admitted to a health system between October 1, 2016, and October 31, 2019. We randomly divided the cohort into development (n = 2,114) and validation (n = 1,089) subcohorts. Nine models were applied to select the most important predictors of 30-day readmission. The final t","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-26T02:39:29.591Z","creation":"2025-02-18T23:32:21.581Z"},"accession":"S-EPMC8522353","cross_references":{"pubmed":["34048528"],"doi":["10.1093/ajhp/zxab223"]}}